Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd banner
J

Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd
SSE:688076

Watchlist Manager
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd
SSE:688076
Watchlist
Price: 29.02 CNY -2.85% Market Closed
Market Cap: ¥9.2B

Income Statement

Earnings Waterfall
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd

Income Statement
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024 Dec-2024 Mar-2025 Jun-2025 Sep-2025
Revenue
Interest Expense
12
5
5
5
6
5
5
7
9
12
13
14
16
19
23
28
35
41
0
0
Revenue
567
N/A
687
+21%
660
-4%
642
-3%
644
+0%
612
-5%
603
-1%
576
-4%
651
+13%
725
+11%
784
+8%
979
+25%
1 034
+6%
1 181
+14%
1 464
+24%
1 576
+8%
1 625
+3%
1 835
+13%
1 842
+0%
1 900
+3%
Gross Profit
Cost of Revenue
(245)
(286)
(285)
(276)
(299)
(284)
(284)
(273)
(302)
(316)
(327)
(387)
(432)
(435)
(513)
(518)
(561)
(589)
(585)
(634)
Gross Profit
322
N/A
401
+24%
375
-6%
366
-2%
345
-6%
328
-5%
319
-3%
303
-5%
349
+15%
409
+17%
457
+12%
591
+29%
601
+2%
746
+24%
951
+27%
1 058
+11%
1 063
+0%
1 246
+17%
1 257
+1%
1 266
+1%
Operating Income
Operating Expenses
(162)
(185)
(201)
(217)
(216)
(254)
(271)
(281)
(262)
(302)
(313)
(374)
(404)
(497)
(545)
(580)
(596)
(676)
(697)
(679)
Selling, General & Administrative
(105)
(141)
(144)
(155)
(140)
(169)
(182)
(188)
(179)
(213)
(226)
(261)
(258)
(312)
(336)
(351)
(354)
(402)
(427)
(413)
Research & Development
(53)
(66)
(66)
(62)
(57)
(61)
(65)
(68)
(62)
(77)
(76)
(105)
(106)
(171)
(198)
(212)
(198)
(240)
(239)
(241)
Depreciation & Amortization
(30)
0
0
0
(27)
0
0
0
(33)
0
0
0
(52)
0
0
0
(54)
0
0
0
Other Operating Expenses
25
20
8
(0)
8
(23)
(23)
(25)
13
(12)
(11)
(8)
12
(14)
(12)
(16)
10
(35)
(32)
(24)
Operating Income
160
N/A
216
+35%
174
-19%
149
-14%
129
-13%
74
-43%
48
-36%
21
-55%
88
+308%
107
+23%
144
+34%
217
+51%
198
-9%
249
+26%
406
+63%
478
+18%
468
-2%
570
+22%
559
-2%
587
+5%
Pre-Tax Income
Interest Income Expense
(18)
(26)
(25)
(16)
1
5
29
28
(0)
12
(10)
(14)
(8)
(7)
(12)
(20)
(19)
(25)
(30)
(37)
Non-Reccuring Items
2
0
0
0
(1)
0
0
19
37
19
19
0
0
0
0
0
(0)
0
0
0
Gain/Loss on Disposition of Assets
0
0
0
0
(1)
0
0
0
(0)
0
0
0
(15)
0
0
0
(9)
0
0
0
Total Other Income
3
0
3
3
(2)
(3)
(4)
(3)
(1)
(7)
(7)
(7)
(1)
(11)
(12)
(15)
(1)
(10)
(7)
(6)
Pre-Tax Income
147
N/A
190
+30%
152
-20%
136
-10%
126
-7%
76
-40%
73
-4%
65
-10%
123
+88%
132
+7%
146
+11%
196
+34%
173
-11%
230
+33%
382
+66%
444
+16%
439
-1%
535
+22%
521
-3%
545
+4%
Net Income
Tax Provision
(27)
(34)
(27)
(25)
(17)
(6)
4
7
(0)
(5)
(15)
(31)
(8)
(19)
(25)
(18)
(39)
(52)
(51)
(49)
Income from Continuing Operations
120
156
124
111
109
70
76
73
123
127
131
164
165
211
357
426
400
483
470
495
Income to Minority Interest
3
3
2
2
7
6
7
7
6
7
5
3
(3)
(3)
(9)
(4)
5
8
17
3
Net Income (Common)
123
N/A
159
+29%
126
-21%
113
-11%
115
+2%
76
-34%
84
+9%
80
-4%
129
+61%
134
+4%
136
+2%
168
+23%
163
-3%
208
+28%
348
+67%
421
+21%
404
-4%
491
+21%
487
-1%
499
+2%
EPS (Diluted)
0.55
N/A
0.71
+29%
0.49
-31%
0.38
-22%
0.42
+11%
0.25
-40%
0.27
+8%
0.26
-4%
0.43
+65%
0.44
+2%
0.45
+2%
0.56
+24%
0.55
-2%
0.69
+25%
1.05
+52%
1.36
+30%
1.31
-4%
1.56
+19%
1.53
-2%
1.6
+5%
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett